A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence - Quiz - MDSpire

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • By

  • Jonathan I. Silverberg

  • Alan D. Irvine

  • Peter Foley

  • James Del Rosso

  • Luis Puig

  • Linda Stein Gold

  • Masahiro Kamata

  • Andreas Wollenberg

  • H. Chih-ho Hong

  • Chia-Yu Chu

  • Yousef Binamer

  • Martin Dossenbach

  • Marta Casillas

  • Gaia Gallo

  • Buelent Akmaz

  • Kim Rand

  • Raj Chovatiya

  • June 17, 2026

  • 0 min

Share

Original Source(s)

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • by Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya

  • June 17, 2026

Related Content

Prognostic model for three-year postoperative local recurrence in cutaneous squamous cell carcinoma: a Chinese multicenter cohort study

Editorial: Immune-related biomarkers in skin and breast cancer: innovations in immunological diagnostics and therapies

Enhanced Diagnosis of Generalized Pustular Psoriasis With the Legit.Health Device as a Diagnosis Support Tool: Multireader Multicase Study